Royal Wulingshan Ginseng (Panax ginseng)

Royal Wulingshan Ginseng is a cultivar of Panax ginseng grown in the Wulingshan mountain region of China, prized for its high ginsenoside concentration—particularly Rb1, Rg1, and Re—which are the primary triterpene saponins responsible for its adaptogenic and neuroprotective properties. These ginsenosides modulate the hypothalamic-pituitary-adrenal axis and interact with steroid hormone receptors to support stress resilience and energy metabolism.

Origin & History

Royal Wulingshan Ginseng is a cultivar variant of Panax ginseng developed through selective breeding programs in China, emphasizing higher ginsenoside content, disease resistance, and superior root morphology including longer main roots (7.4-8.6 cm) and heavier weights (73-78 g). The roots are typically harvested after 4-6 years and processed via steaming and drying into red ginseng.

Historical & Cultural Context

Royal Wulingshan Ginseng, as a Panax ginseng cultivar, shares the historical context of P. ginseng in Traditional Chinese Medicine and Korean traditional medicine, used for vitality, fatigue, and adaptogenic effects over centuries. This modern cultivar was developed recently (20-24 years via hybridization or line selection) to improve upon landraces for yield and quality.

Health Benefits

• No clinical evidence specific to Royal Wulingshan Ginseng cultivar exists in the research
• General Panax ginseng traditionally used for vitality and fatigue (Traditional evidence only)
• Higher ginsenoside content in Chinese cultivars may enhance adaptogenic effects (No clinical studies provided)
• Disease-resistant cultivar may offer cleaner product free from fungal contamination (Agricultural trait only)
• Superior root morphology suggests potential for higher active compound yield (No human studies available)

How It Works

Ginsenosides Rb1 and Rg1 in Royal Wulingshan Ginseng act as ligands for glucocorticoid and estrogen receptors, modulating HPA axis activity and attenuating cortisol dysregulation under stress. Rb1 upregulates BDNF expression and inhibits acetylcholinesterase, supporting cholinergic neurotransmission and cognitive function, while Rg1 activates PI3K/Akt and AMPK signaling pathways to enhance mitochondrial ATP production and reduce oxidative stress via Nrf2 pathway activation. Compound K, a gut-derived metabolite of protopanaxadiol ginsenosides, further contributes anti-inflammatory effects by suppressing NF-κB activation and inhibiting COX-2 expression.

Scientific Research

No clinical trials, RCTs, or meta-analyses specifically on Royal Wulingshan Ginseng were identified in the research. The provided sources focus exclusively on agronomic traits like growth, yield, and ginsenoside content rather than clinical outcomes, with no PubMed PMIDs for human trials linked to this cultivar.

Clinical Summary

No peer-reviewed clinical trials have been conducted specifically on the Royal Wulingshan cultivar of Panax ginseng, meaning cultivar-specific efficacy claims lack direct human evidence. Broader Panax ginseng research provides the closest applicable data: a 2013 randomized controlled trial (n=90) found standardized Panax ginseng extract (200–400 mg/day) significantly reduced fatigue scores compared to placebo over 8 weeks. A 2020 meta-analysis of 7 RCTs suggested Panax ginseng improved cognitive performance and working memory in healthy adults, though effect sizes were modest and study heterogeneity was high. Until cultivar-specific studies are conducted, any claimed superiority of the Wulingshan cultivar based on ginsenoside content remains theoretical and should be interpreted cautiously.

Nutritional Profile

Royal Wulingshan Ginseng (Panax ginseng) is a specialty cultivar grown in the Wulingshan mountain region of China. As a root-based botanical, macronutrient composition per 100g dried root is estimated as: carbohydrates 60-70g (primarily ginsan polysaccharides and starch), protein 10-15g (including arginine-rich peptides), fat 1-2g, fiber 8-12g (including pectic polysaccharides). Key bioactive compounds include ginsenosides (total saponin content estimated 3-8% by dry weight in Chinese mountain cultivars, potentially higher than Korean cultivars at 2-4%; predominant ginsenosides include Rb1, Rb2, Rc, Rd, Re, Rg1, Rg3, and Rh2). Panaxanosides and malonyl ginsenosides are also present. Polysaccharides (ginsan) contribute approximately 10-20% dry weight with immunomodulatory properties. Micronutrients include potassium (estimated 500-700mg/100g dried), calcium (60-80mg/100g), magnesium (40-60mg/100g), zinc (1-3mg/100g), iron (3-5mg/100g), and manganese (1-2mg/100g). Minor volatile oils (0.05-0.15%) contain sesquiterpenes including panasinsene and elemene. Bioavailability of ginsenosides is limited by poor oral absorption; gut microbiota convert protopanaxadiol ginsenosides (Rb1, Rc, Rd) into more bioavailable compound K. The disease-resistant cultivar characteristic may reduce mycotoxin contamination, potentially supporting a cleaner ginsenoside profile without degradation. No cultivar-specific quantified nutritional data has been independently published for Royal Wulingshan Ginseng specifically.

Preparation & Dosage

No clinically studied dosage ranges are available for Royal Wulingshan Ginseng specifically, as the research lacks human trial data. For Panax ginseng cultivars generally, standardization targets ginsenosides, but no specific extract, powder, or standardized form dosages from studies are detailed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

American ginseng, Rhodiola rosea, Cordyceps, Schisandra, Eleuthero

Safety & Interactions

Panax ginseng is generally well-tolerated at doses of 200–400 mg of standardized extract daily, with the most commonly reported side effects being insomnia, headache, digestive upset, and mild hypertension, particularly at higher doses. It has a clinically significant interaction with warfarin, as ginsenosides can inhibit CYP2C9 and alter platelet aggregation, potentially increasing bleeding risk, and it should not be combined with MAO inhibitors due to risk of manic episodes and hypertension. Ginseng may exert estrogen-like effects and is therefore contraindicated in individuals with hormone-sensitive conditions such as breast cancer, uterine fibroids, or endometriosis. Use during pregnancy and lactation is not recommended due to insufficient safety data, and the compound ginsenoside Rf has shown embryotoxic effects in animal models.